To start, I will address the first part of your question.
I think it behooves me to correct a common misunderstanding or misapprehension about R and D costs related to very rare orphan drugs. If you look at the literature, it's pretty clear that R and D costs to bring a drug for a very rare disease to market are only a fraction of the R and D costs of a more common or conventional drug that isn't designated as an orphan. It's somewhere in the order of 25%. The real issue, I guess, is the small patient population and what opportunity that provides to recoup drug costs at the end of the day.
Some people have suggested that the profit margins for companies that are bringing forward orphan drugs are well in excess of the profit margins for companies that are producing more conventional drugs. That might be something that's worth taking a look at over the long term. It's just very difficult to disentangle R and D costs for a lot of these big multinational companies, but I can tell you that in our experience, looking at companies that are single-product and that produce orphan drugs, sometimes we're seeing gross profit margins in the order of 90%. That is—